Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A ...
A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans ...
A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans to ...
Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
BARCELONA - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate ...
BARCELONA - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company, has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate ...